Trastuzumab for the Treatment of HER2-Positive Metastatic Gastric Cancer: A NICE Single Technology Appraisal

Eldon Spackman; Stephen Rice; Gill Norman; Dong-Churl Suh; Alison Eastwood; Stephen Palmer

doi:10.1007/s40273-013-0023-z

Trastuzumab for the Treatment of HER2-Positive Metastatic Gastric Cancer: A NICE Single Technology Appraisal

Eldon Spackman, Stephen Rice, Gill Norman, Dong-Churl Suh, Alison Eastwood, Stephen Palmer

Research output: Contribution to journal › Article › peer-review

Abstract

The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of trastuzumab, Roche Pharmaceuticals, to submit evidence for the clinical and cost effectiveness of this drug for the treatment of advanced gastric cancer (aGC), as part of the Institute's single technology appraisal (STA) process. The Centre for Reviews and Dissemination (CRD) and the Centre for Health Economics (CHE) Technology Appraisal Group at the University of York was commissioned to act as the evidence review group (ERG). This article provides a description of the company submission, the ERG report and NICE's subsequent decisions. In the initial appraisal by NICE, trastuzumab was rejected for use in the licensed population. Given this result, the manufacturer submitted additional evidence. In the final appraisal decision, trastuzumab was approved, in accordance with supplementary guidance issued by NICE on appraising life-extending, end-of-life treatments, for patients whose human epidermal growth factor receptor 2 (HER2) status was defined by an immunohistochemistry 3 positive (IHC3+) result. This appraisal highlights the need to fully assess the impact of different approaches to diagnostic testing on the cost effectiveness of targeted treatments. In this appraisal, it was found that the diagnostic strategy influenced the effectiveness and cost of trastuzumab. In the future, different diagnostic strategies should be compared in the incremental cost-effectiveness analysis.

Original language	English
Pages (from-to)	185-194
Number of pages	9
Journal	Pharmacoeconomics
Volume	31
Issue number	3
DOIs	https://doi.org/10.1007/s40273-013-0023-z
Publication status	Published - Mar 2013

Access to Document

10.1007/s40273-013-0023-z

http://link.springer.com/article/10.1007%2Fs40273-013-0023-z

Cite this

@article{c3779881ac1147c8a5786779f9d7d0d3,

title = "Trastuzumab for the Treatment of HER2-Positive Metastatic Gastric Cancer: A NICE Single Technology Appraisal",

abstract = "The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of trastuzumab, Roche Pharmaceuticals, to submit evidence for the clinical and cost effectiveness of this drug for the treatment of advanced gastric cancer (aGC), as part of the Institute's single technology appraisal (STA) process. The Centre for Reviews and Dissemination (CRD) and the Centre for Health Economics (CHE) Technology Appraisal Group at the University of York was commissioned to act as the evidence review group (ERG). This article provides a description of the company submission, the ERG report and NICE's subsequent decisions. In the initial appraisal by NICE, trastuzumab was rejected for use in the licensed population. Given this result, the manufacturer submitted additional evidence. In the final appraisal decision, trastuzumab was approved, in accordance with supplementary guidance issued by NICE on appraising life-extending, end-of-life treatments, for patients whose human epidermal growth factor receptor 2 (HER2) status was defined by an immunohistochemistry 3 positive (IHC3+) result. This appraisal highlights the need to fully assess the impact of different approaches to diagnostic testing on the cost effectiveness of targeted treatments. In this appraisal, it was found that the diagnostic strategy influenced the effectiveness and cost of trastuzumab. In the future, different diagnostic strategies should be compared in the incremental cost-effectiveness analysis.",

author = "Eldon Spackman and Stephen Rice and Gill Norman and Dong-Churl Suh and Alison Eastwood and Stephen Palmer",

year = "2013",

month = mar,

doi = "10.1007/s40273-013-0023-z",

language = "English",

volume = "31",

pages = "185--194",

journal = "Pharmacoeconomics",

issn = "1170-7690",

publisher = "Adis International Ltd",

number = "3",

}

TY - JOUR

T1 - Trastuzumab for the Treatment of HER2-Positive Metastatic Gastric Cancer

T2 - A NICE Single Technology Appraisal

AU - Spackman, Eldon

AU - Rice, Stephen

AU - Norman, Gill

AU - Suh, Dong-Churl

AU - Eastwood, Alison

AU - Palmer, Stephen

PY - 2013/3

Y1 - 2013/3

N2 - The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of trastuzumab, Roche Pharmaceuticals, to submit evidence for the clinical and cost effectiveness of this drug for the treatment of advanced gastric cancer (aGC), as part of the Institute's single technology appraisal (STA) process. The Centre for Reviews and Dissemination (CRD) and the Centre for Health Economics (CHE) Technology Appraisal Group at the University of York was commissioned to act as the evidence review group (ERG). This article provides a description of the company submission, the ERG report and NICE's subsequent decisions. In the initial appraisal by NICE, trastuzumab was rejected for use in the licensed population. Given this result, the manufacturer submitted additional evidence. In the final appraisal decision, trastuzumab was approved, in accordance with supplementary guidance issued by NICE on appraising life-extending, end-of-life treatments, for patients whose human epidermal growth factor receptor 2 (HER2) status was defined by an immunohistochemistry 3 positive (IHC3+) result. This appraisal highlights the need to fully assess the impact of different approaches to diagnostic testing on the cost effectiveness of targeted treatments. In this appraisal, it was found that the diagnostic strategy influenced the effectiveness and cost of trastuzumab. In the future, different diagnostic strategies should be compared in the incremental cost-effectiveness analysis.

AB - The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of trastuzumab, Roche Pharmaceuticals, to submit evidence for the clinical and cost effectiveness of this drug for the treatment of advanced gastric cancer (aGC), as part of the Institute's single technology appraisal (STA) process. The Centre for Reviews and Dissemination (CRD) and the Centre for Health Economics (CHE) Technology Appraisal Group at the University of York was commissioned to act as the evidence review group (ERG). This article provides a description of the company submission, the ERG report and NICE's subsequent decisions. In the initial appraisal by NICE, trastuzumab was rejected for use in the licensed population. Given this result, the manufacturer submitted additional evidence. In the final appraisal decision, trastuzumab was approved, in accordance with supplementary guidance issued by NICE on appraising life-extending, end-of-life treatments, for patients whose human epidermal growth factor receptor 2 (HER2) status was defined by an immunohistochemistry 3 positive (IHC3+) result. This appraisal highlights the need to fully assess the impact of different approaches to diagnostic testing on the cost effectiveness of targeted treatments. In this appraisal, it was found that the diagnostic strategy influenced the effectiveness and cost of trastuzumab. In the future, different diagnostic strategies should be compared in the incremental cost-effectiveness analysis.

U2 - 10.1007/s40273-013-0023-z

DO - 10.1007/s40273-013-0023-z

M3 - Article

C2 - 23371465

SN - 1170-7690

VL - 31

SP - 185

EP - 194

JO - Pharmacoeconomics

JF - Pharmacoeconomics

IS - 3

ER -